Wikisage, the free encyclopedia of the second generation, is digital heritage

Bezafibrate: Difference between revisions

From Wikisage
Jump to navigation Jump to search
No edit summary
 
(5 intermediate revisions by the same user not shown)
Line 1: Line 1:
[[File:Fibrates.svg.png|thumb|450px]]
[[File:Fibrates.svg.png|thumb|450px]]
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases.
This fibrate reduce triglyceride and riseHDL-cholesterol<ref>[https://www.jstage.jst.go.jp/article/jat/22/7/22_ED007/_pdf How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?]</ref><ref>[https://www.jstage.jst.go.jp/article/jat/22/7/22_27425/_pdf Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.]</ref>
This fibrate reduces triglyceride and rises HDL-cholesterol<ref>[https://www.jstage.jst.go.jp/article/jat/22/7/22_ED007/_pdf How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?]</ref><ref>[https://www.jstage.jst.go.jp/article/jat/22/7/22_27425/_pdf Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.]</ref>


<gallery>
<gallery>
Line 10: Line 10:
<ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref>
<ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref>


ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cyrrhosis (See Figure in gallery).
ursodeoxycholic acid and bezafibrate are under study in the treatment of [[biliar cirrhosis]] (See Figure in gallery).
==Links==
==Links==
[http://www.scielo.br/pdf/ag/v51n3/0004-2803-ag-51-03-255.pdf Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?]
[http://www.scielo.br/pdf/ag/v51n3/0004-2803-ag-51-03-255.pdf Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?]
Line 21: Line 21:
|}
|}


<references/>
{{refs}}


[[File:Wikidata-logo-en.svg.png|32px]]
{{Wikidata|Q577387}}
[https://www.wikidata.org/wiki/Q577387 Q577387]


[[Category:Hepatotoxic substances]]
[[Category:Hepatotoxic substances]]

Latest revision as of 23:14, 26 February 2019